Radiotherapy for elderly glioblastoma
- Conditions
- Neoplasms
- Registration Number
- KCT0007527
- Lead Sponsor
- Seoul Metropolitan Government Seoul National University Boramae Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 268
1.newly diagnosed glioblastoma according to the 2021 WHO classification
2.interval of =4 weeks between pathological diagnosis and randomization
3.aged 70 years or older
4.gadolinium-enhanced MRI within 72 hours of surgery
5.known o6-methylguanine-DNA-methyltransferase promoter methylation status
6.Karnofsky performance score =60
7.stable or decreasing dose of steroid (if necessary)
8.no history of brain radiotherapy
9.no history of any systemic chemotherapy
10.adequate hematological, renal and hepatic functions for temozolomide
11.able to start radiotherapy within 3 weeks from randomization
1.patients with spinal leptomeningeal carcinomatosis
2.history of cancer other than the followings: carcinoma in situ of the cervix, completely excised non-melanoma skin cancer, cancers without any evidence of residual disease for 5 years or longer
3.patients with serious active infection or other serious underlying medical conditions
4.patients with psychological issues that cannot comply to the protocol
5.patients with known hypersensitivity to temozolomide or compounds with similar chemical composition to temozolomide
6.patients who are currently participating in other clinical trials
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method progression-free survival